99 related articles for article (PubMed ID: 15908979)
1. Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin-tazobactam.
Solano C; Gutierrez A; Martinez F; Gimeno C; Gómez C; Muñoz I; Faus F; Goterris R; Farga A; Navarro D
Bone Marrow Transplant; 2005 Jul; 36(1):59-65. PubMed ID: 15908979
[TBL] [Abstract][Full Text] [Related]
2. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
5. A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Nguyen AD; Heil EL; Patel NK; Duffy A; Gilmore S
J Oncol Pharm Pract; 2016 Apr; 22(2):303-7. PubMed ID: 25567517
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Rizal AM; Nordiah AJ; Jamal R
Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
8. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies.
Hazel DL; Graham J; Dickinson JP; Newland AC; Kelsey SM
J Chemother; 1997 Aug; 9(4):267-72. PubMed ID: 9269607
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation.
Kroschinsky F; Wichmann G; Bornhauser M; Ordemann R; Schuler U; Ehninger G; Hanel M
Transpl Infect Dis; 2002 Sep; 4(3):132-6. PubMed ID: 12421457
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients.
Ram R; Farbman L; Leibovici L; Raanani P; Yeshurun M; Vidal L; Gafter-Gvili A; Peck A; Shpilberg O; Paul M
Int J Antimicrob Agents; 2012 Aug; 40(2):123-6. PubMed ID: 22727772
[TBL] [Abstract][Full Text] [Related]
12. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies.
Fernández-Avilés F; Carreras E; Urbano-Ispizua A; Rovira M; Martínez C; Gaya A; Granell M; Ramiro L; Gallego C; Hernando A; Segura S; García L; González M; Valverde M; Montserrat E
J Clin Oncol; 2006 Oct; 24(30):4855-61. PubMed ID: 17001069
[TBL] [Abstract][Full Text] [Related]
13. [The prophylactic effect of ceftazidime on early bacterial infection after autologous peripheral blood stem cell transplantation: a prospective randomized controlled trial].
Duan MH; Zhu TN; Han B; Li J; Zhou DB
Zhonghua Nei Ke Za Zhi; 2013 Nov; 52(11):956-60. PubMed ID: 24439191
[TBL] [Abstract][Full Text] [Related]
14. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF.
Offidani M; Corvatta L; Olivieri A; Rupoli S; Frayfer J; Mele A; Manso E; Montanari M; Centurioni R; Leoni P
Bone Marrow Transplant; 1999 Nov; 24(10):1079-87. PubMed ID: 10578158
[TBL] [Abstract][Full Text] [Related]
15. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Cornely OA; Wicke T; Seifert H; Bethe U; Schwonzen M; Reichert D; Ullmann AJ; Karthaus M; Breuer K; Salzberger B; Diehl V; Fätkenheuer G
Int J Hematol; 2004 Jan; 79(1):74-8. PubMed ID: 14979482
[TBL] [Abstract][Full Text] [Related]
16. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
[TBL] [Abstract][Full Text] [Related]
17. [Microbiological characteristics of pathogens causing bacteremia among hospitalized pediatric oncology patients with fever and neutropenia].
Leibson T; Ben-Shimol S; Hazan G; Fruchtman Y; Kapelushnik J; Greenberg D
Harefuah; 2012 Oct; 151(10):592-6, 603-4. PubMed ID: 23316669
[TBL] [Abstract][Full Text] [Related]
18. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
Bucaneve G; Micozzi A; Picardi M; Ballanti S; Cascavilla N; Salutari P; Specchia G; Fanci R; Luppi M; Cudillo L; Cantaffa R; Milone G; Bocchia M; Martinelli G; Offidani M; Chierichini A; Fabbiano F; Quarta G; Primon V; Martino B; Manna A; Zuffa E; Ferrari A; Gentile G; Foà R; Del Favero A
J Clin Oncol; 2014 May; 32(14):1463-71. PubMed ID: 24733807
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
Jing Y; Li J; Yuan L; Zhao X; Wang Q; Yu L; Zhou D; Huang W
Clin Transplant; 2016 Mar; 30(3):263-9. PubMed ID: 26701371
[TBL] [Abstract][Full Text] [Related]
20. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
Karaman S; Vural S; Yildirmak Y; Emecen M; Erdem E; Kebudi R
Pediatr Blood Cancer; 2012 Apr; 58(4):579-83. PubMed ID: 21674768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]